Abstract:Background Primary Sjogren's syndrome (pSS) is a chronic, systemic autoimmune disorder characterized by inflammation of exocrine glands and functional impairment of the salivary and lacrimal glands [1]. The pathogenesis of pSS is complicated with many respects remaining elusive. Interleukin-27 (IL-27) is a new member of the IL-12 cytokine family. It is largely secreted by activated antigen-presenting cells, such as macrophages and dendritic cells (DCs). IL-27 participates in multiple autoimmune diseases by regulating T lymphocyte subsets. Recent studies showed that IL-27 was involved in anti-inflammatory functions in SS [2]. However, the underlying mechanism of IL-27 in SS is still unknown. Objectives In the present study, the changes of lymphocyte subsets were studied in Il-27 knock-out and wild-type pSS models and pSS patients for the purpose to explore the specific mechanism of IL-27 in pSS and provide the basis for clinical treatment. Methods The NOD mice, Il-27 knockout (Il-27–/–) mice, Il-27 knockout mice with recombinant IL-27 treatment were studied. The saliva flow rates, weight, weight of submandibular glands and spleens were detected. Murine submandibular glands were fixed and paraffin sections were used for hematoxylin and eosin staining. The lymphocyte subsets of spleens from experimental mice and the peripheral blood from pSS patients were measured by flow-cytometric assay. Results Compared to WT NOD mice, the saliva flow rates decreased significantly, and the indexes of submandibular glands and spleens increased significantly in Il-27–/– mice (Fig 1A-E). The histological results showed that the number of lymphocytic infiltrates in submandibular glands of WT NOD was lower than Il-27–/– mice (Fig 1F). The splenic-Treg cells decreased significantly, but the levels of splenic Th17 and B cells increased significantly in Il-27–/– mice. After IL-27 treatment, the saliva flow rates, submandibular glands, Treg and Th17 cells were partially reversed in Il-27–/– mice (Fig 1G-M). Consistent with above observations, the changes of Terg and Th17 cells in pSS patients showed similar pattern. The Th2, Tfh and plasma cells increased significantly, whilst the B cells decreased significantly in pSS patients (Fig 1N-T). Compared with healthy control, the serum IL-27 decreased in pSS patients. Conclusions In general, these findings indicated that IL-27 deficiency deteriorated the disease symptoms of pSS and resulted in changes of Th17/Treg balance. In addition, pSS patients showed similar lymphocyte imbalance. Our data suggested that IL-27 might play an important role on the development and pathogenesis of pSS through regulating lymphocyte subsets, and targeting IL-27 and Th17/Treg balance may be a new direction of pSS treatment. References Xu J, Wang D, Liu D, et al. Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjogren syndrome. Blood, 2012, 120(15): 3142–3151. Lee BH, Carcamo WC, Chiorini JA, et al. Gene therapy using IL-27 ameliorates Sjögren's syndrome-like autoimmune exocrinopathy. Arthritis Res Ther, 2012, 14(4): R172. Disclosure of Interest None declared

Pharmacological Inhibition of Glutaminase 1 Normalized the Metabolic State and CD4+T Cell Response in Sjogren's Syndrome

Pharmacological Inhibition of Glutaminase 1 Normalized the Metabolic State and CD4+ T Cell Response in Sjogren’s Syndrome

Total Glucosides of Peony Ameliorates Sjögren's Syndrome by Affecting Th1/Th2 Cytokine Balance.

Follicular Helper T Cells and Follicular Regulatory T Cells in the Immunopathology of Primary Sjögren's Syndrome

Follicular helper T cells and follicular regulatory T cells in the immunopathology of primary Sjogren's syndrome

Sphingosine-1-phosphate Alleviates Sjögren’s Syndrome-Like Symptoms Via Inducing Autophagy and Regulating Status of Treg Cells in NOD Mice

Proteasome Inhibition Suppresses Th17 Cell Generation and Ameliorates Autoimmune Development in Experimental Sjögren’s Syndrome

Immunometabolic alteration of CD4+ T cells in the pathogenesis of primary Sjögren's syndrome

Mesenchymal Stem Cell Transplantation Alleviates Sjögren's Syndrome Symptoms Through Tim-3 Signaling in T Cells

OP0166 Il-27 Participates in Sjogren's Syndrome by Regulating Lymphocyte Subsets

Total Glucosides of Paeony (TGP) Alleviates Sjogren's Syndrome Through Inhibiting Inflammatory Responses in Mice.

Umbilical Cord Mesenchymal Stem Cells Alleviate Sjögren's Syndrome and Related Pulmonary Inflammation Through Regulating Vγ4+ IL-17+ T Cells.

Altered characteristics of regulatory T cells in target tissues of Sjögren's syndrome in murine models

Spontaneous Colitis in IL-10-deficient Mice Was Ameliorated Via Inhibiting Glutaminase1

Inhibition of glutaminolysis ameliorates lupus by regulating T and B cell subsets and downregulating the mTOR/P70S6K/4EBP1 and NLRP3/caspase-1/IL-1β pathways in MRL/lpr mice

Iguratimod Suppresses Plasma Cell Differentiation and Ameliorates Experimental Sjögren’s Syndrome in Mice by Promoting TEC Kinase Degradation

A GITRL-mTORC1-GM-CSF Positive Loop Promotes Pathogenic Th17 Response in Primary Sjögren Syndrome.

Total glucosides of paeony alleviates experimental Sjögren's syndrome through inhibiting NLRP3 inflammasome activation of submandibular gland cells

A GITRL‐mTORC1‐GM‐CSF positive loop promotes pathogenic Th17 response in exacerbating Primary Sjögren's Syndrome

Iguratimod suppresses plasma cell differentiation and ameliorates experimental Sjögren's syndrome in mice by promoting TEC kinase degradation

Subpopulation dynamics of T and B lymphocytes in Sjögren's syndrome: implications for disease activity and treatment